Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Query: "TILT[LastUpdatePostDate]SEARCH[Study]AREA[SponsorSearch]Supernus Pharmaceuticals, Inc."
Count: 51
Selected: 0
NCT IDTitle
NCT02691182Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 4)
NCT04786990Open-Label Study of SPN-812 Administered With Psychostimulants in Children and Adolescents With ADHD
NCT04050293Therapy for Migraine Prevention in Children 6-11 Years of Age
NCT03597503Treatment of Impulsive Aggression (IA) in Adolescent With ADHD in Conjunction With Standard ADHD Treatment
NCT04781140Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD
NCT06185985Open-label Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD and Mood Symptoms
NCT02618434Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 2)
NCT06259331Evaluation of Viloxazine and Its Metabolite 5-Hydroxy-viloxazine Glucuronide Into Breast Milk in Healthy Lactating Women
NCT04143217Open-label Long-Term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD
NCT02618408Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 1)
NCT03944785Clinical Outcome Assessment of Parkinson's Disease Patients Treated With XADAGO (Safinamide)
NCT02736656Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 Extended Release (ER)
NCT05518578Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant Epilepsy
NCT04815967Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity
NCT04099667Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Lower Limb Spasticity
NCT05097079Efficacy and Safety Study of MYOBLOC® in the Treatment of Sialorrhea in Pediatric Subjects
NCT05102552Evaluating the Safety and Relative Bioavailability of Three SPN-817 Treatments (A, B and C) in Healthy Adult Subjects
NCT03474770BIS-001-ER for the Treatment of Adult Focal Impaired Awareness Seizures
NCT04016779Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD
NCT05384977Mass Balance Study of NV-5138 in Healthy Male Subjects
NCT03638466Exploratory fMRI Study on the Treatment for Impulsive Aggression in Children With Attention-Deficit/Hyperactivity Disorder
NCT02633527Efficacy and Safety of SPN-812 (Viloxazine Extended-release Capsule) in Children With ADHD
NCT02610868Open-Label and Single-Arm Study of MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adults
NCT01994109Efficacy and Safety Study of MYOBLOC® Followed by Open-Label Multiple-Treatment With MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adult Subjects
NCT03247543Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Children With ADHD
NCT03247556Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Adolescents With ADHD
NCT03247530Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Children With ADHD
NCT03247517Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Adolescents With ADHD
NCT01364662A Study to Evaluate the Efficacy and Safety of SPN-810 as Adjunctive Therapy in Children With Impulsive Aggression Comorbid With Attention-Deficit/Hyperactivity Disorder (ADHD)
NCT04016792Classroom Study of SPN-812 in Children With ADHD
NCT03615703Functional MRI Study in Healthy Children Engaged in Aggressive Behaviors
NCT03156439Bioavailability, Safety, and Tolerability of BIS-001 ER
NCT00918047Study of PK and Safety of OXC (Oxcarbazepine) XR (Extended Release) as Adjunctive Therapy in Pediatric Epilepsy Patients
NCT00908349Safety and Tolerability of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Epilepsy
NCT01114854A Conversion Study of Immediate Release (IR) and Modified Release (MR) Forms of Topiramate (TPM)
NCT00918424Long Term Study of the Safety of OXC XR as in Pediatric Epilepsy Subjects
NCT01107496A Phase I/IIa, Randomized, Double-Blind Study of the Safety and Efficacy of SPN-812 in Adults With ADHD
NCT01416064Open-Label, Extension Study to 810P202
NCT01284530Evaluation of the Pharmacokinetics, Safety, and Tolerability of TPM XR as Adjunctive Therapy in Pediatric Subjects With Epilepsy
NCT02023606Phase I Study to Assess the Absorption, Metabolism, and Excretion of [14C] Labeled SPN-810M
NCT00772603Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures
NCT00626236Phase 2a Study of Safety and Tolerability of SPN-810 in Children With ADHD and Persistent Serious Conduct Problems
NCT06235905Open-Label of SPN-820 in Adults With Major Depressive Disorder
NCT05066672Phase 2 Study of NV-5138 in Adults With Treatment Resistant Depression
NCT05152680Mass Balance Study of NV-5138 in Healthy Male Subjects.
NCT03280342Cognitive Effects of Immediate Release Topiramate vs Extended Release Topiramate in Patients With Migraine
NCT02339064Infusion of Apomorphine: Long-term Safety Study
NCT02549573Outpatient Physical Therapy Intervention in Subjects With Parkinson's Disease Currently Using APOKYN®
NCT01770145Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)
NCT01246765National Pregnancy Registry for Psychiatric Medications